Learning from lecanemab: a breakthrough treatment

Here, Dr Michael Irizarry from Eisai discusses the company's highly anticipated Alzheimer’s drug, lecanemab.

Related Keywords

Japan ,Harvard School Of Public Health ,Massachusetts ,United States ,Eli Lilly ,Michael Irizarry ,Glaxosmithkline ,Drug Administration ,Brain Health ,Georgetown University ,Master Of Public Health ,European Medicines Agency ,Clinical Research ,Brain Health At Eisai ,Massachusetts Alzheimer Disease Research Center ,Senior Vice President ,Deputy Chief Clinical Officer ,Accelerated Approval ,Priority Review ,Supplemental Biologics License Application ,Right Hypothesis ,Right Population ,Right Dosage ,Confidence Interval ,New England Journal ,Vice President ,Massachusetts Alzheimer ,Disease Research ,Public Health ,Harvard School ,